| Objective:To analyze the utilization of anticancer adjuvant therapeutic drugs in the Second Hospital of Tianjin Medical University in recent five years and study the cardioprotective effects of anticancer adjuvant therapeutic drugs on cardiac injury induced by anthracyclines, also study the improvement of quality of lifeMethods:Mono-center, retrospective, nonrandomized concurrent controlled study was introduced. The utilization data of these medicines in the hospital from2007to2011was analyzed statistically by the sequencing of consumption sum and defined daily dose (DDD) method. The research medicines were selected according to " widely used, lower DDC ". The medical records of262postoperative breast cancer patients were consulted retrospectively, who received anthracycline chemotherapy. The patients were divided into observation groups (SQFZ group, CP group, SQFZ+CP group and TAM group) and control groups according to assistant therapy. The four observation groups were treated with different adjuvant drugs, which were given synchronously with chemotherapyResults:The consumption amount and DDDs of these medicines increased year by year, while defined daily cost (DDC) showed decreasing trends. In the observation groups, myocardial injury was improved, especially in SQFZ+CP group. Cardiac function was better than those in the control group. Quality of life was better in SQFZ group and SQFZ+CP group. However, it was worse in TAM groupConclusion:The utilization of anticancer adjuvant therapeutic drugs in our hospital is relatively rational. SQFZ and CP protect cardiac tissue against anthracycline, meanwhile enhance quality of life for breast cancer patients TAM protects cardiac tissue slightly, which is useless for improving quality of life. Synergy effect is found between SQFZ and CP in cardioprotection. |
PDF Full Text Request